Back to top
more

Amgen (AMGN)

(Delayed Data from NSDQ)

$321.91 USD

321.91
2,654,799

+0.12 (0.04%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $321.92 +0.01 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

GSK Gears Up for Q3 Earnings: Will It Surpass Estimates?

by Zacks Equity Research

We expect GSK's specialty products like Cabenuva, Juluca, Dovato, Bexsero, Trelegy Ellipta and Shingrix to drive third-quarter sales performance.

The Zacks Analyst Blog Highlights Apple, Amgen, Becton, Dickinson, UnitedHealth and Verisk

by Zacks Equity Research

Apple, Amgen, Becton, Dickinson, UnitedHealth and Verisk are included in this Analyst Blog.

Abhinab Dasgupta headshot

Take the Zacks Approach to Beat the Market: Novo Nordisk, Amgen, Fabrinet in Focus

by Abhinab Dasgupta

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

AbbVie (ABBV) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

AbbVie's (ABBV) Q3 performance will likely reflect its newer immunotherapy drugs trying to compensate for declining Humira sales following the loss of U.S. exclusivity.

Sheraz Mian headshot

Top Stock Reports for Apple, Amgen & Becton, Dickinson

by Sheraz Mian

Today's Research Daily features new research reports on 12 major stocks, including Apple Inc. (AAPL), Amgen Inc. (AMGN) and Becton, Dickinson and Company (BDX).

Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for PJP

Amgen (AMGN) Stock Moves -0.3%: What You Should Know

by Zacks Equity Research

Amgen (AMGN) closed the most recent trading day at $283.58, moving -0.3% from the previous trading session.

5 Biotech Stocks Set to Outpace Q3 Earnings Estimates

by Zacks Equity Research

Let us look at some biotech stocks, AMGN, BIIB, GSK, PRTA and VRTX, which are poised to beat on third-quarter earnings.

PBYI vs. AMGN: Which Stock Is the Better Value Option?

by Zacks Equity Research

PBYI vs. AMGN: Which Stock Is the Better Value Option?

Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know

by Zacks Equity Research

Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Will Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Abhinab Dasgupta headshot

Beat the Market the Zacks Way: Novo Nordisk, MakeMyTrip, Fastenal in Focus

by Abhinab Dasgupta

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

(AMGN) Rises As Market Takes a Dip: Key Facts

by Zacks Equity Research

In the closing of the recent trading day, Amgen (AMGN) stood at $285.04, denoting a +0.51% change from the preceding trading day.

Amgen's (AMGN) Stock Rallies Almost 5% on Broker Upgrade

by Zacks Equity Research

A Leerink Partner analyst expects accelerating pipeline news flow for Amgen (AMGN).

Sheraz Mian headshot

Top Research Reports for Meta Platforms, Eli Lilly & Caterpillar

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Meta Platforms, Inc. (META), Eli Lilly and Company (LLY) and Caterpillar Inc. (CAT).

Should You Invest in the VanEck Biotech ETF (BBH)?

by Zacks Equity Research

Sector ETF report for BBH

Mirati (MRTX) Gets Buyout Offer From Bristol Myers for $4.8B

by Zacks Equity Research

Sanofi (SNY) is set to acquire Mirati (MRTX) for $58 per share in cash along with a contingent value right of $12 per share, tied to a regulatory milestone.

Coherus (CHRS) Stock Rises on BLA Re-Filing for Udenyca Onbody

by Zacks Equity Research

Coherus (CHRS) resubmits biologics license application for Udenyca Onbody, an on-body injector presentation of Udenyca to the FDA. Stock rises.

Santanu Roy headshot

Beat the Market the Zacks Way: UnitedHealth, Novo Nordisk, Check Point Software in Focus

by Santanu Roy

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

Amgen (AMGN) Increases Yet Falls Behind Market: What Investors Need to Know

by Zacks Equity Research

Amgen (AMGN) closed at $267.47 in the latest trading session, marking a +0.9% move from the prior day.

Mirati (MRTX) Surges 45% as Sanofi Reportedly Eyes Buyout

by Zacks Equity Research

A Bloomberg article suggests that pharma giant Sanofi (SNY) is exploring a potential acquisition deal for small cancer drugmaker Mirati Therapeutics (MRTX).

Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.

The Zacks Analyst Blog Highlights Amgen, ServiceNow, RTX, Automatic Data Processing and Canadian Pacific Kansas City

by Zacks Equity Research

Amgen, ServiceNow, RTX, Automatic Data Processing and Canadian Pacific Kansas City are included in this Analyst Blog.

Amgen (AMGN) Surpasses Market Returns: Some Facts Worth Knowing

by Zacks Equity Research

Amgen (AMGN) reachead $265.44 at the closing of the latest trading day, reflecting a +1.7% change compared to its last close.